To target HSCs, the primary drivers of fibrosis in MASLD/MASH, several studies have modified the surface receptors of HSCs or specific ligands of highly expressed receptors, such as mannose-6-phosphate/insulin-like growth factor II (M6P/IGF-II) [172], PDGF receptor [173], and retinol-binding protein receptor, on the surface of NPs to selectively deliver antifibrotic drugs to HSCs [174]. The gene discussed is IGF2; the disease is metabolic dysfunction-associated steatotic liver disease.